Soleno Therapeutics Lawsuit Over Misleading DCCR Trial Claims
The Schall Law Firm, a nationwide firm focused on shareholder rights litigation, is alerting investors to a class action lawsuit filed against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 issued by the U.S. Securities and Exchange Commission.
Investors who acquired the company’s securities between March 26, 2025, and November 4, 2025 (the “Class Period”), are urged to reach out to the firm before May 5, 2026.
You are invited to get in touch with Brian Schall at The Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335 to review your legal rights at no cost. Alternatively, you may connect with the firm through its website at www.schallfirm.com or via email at bschall@schallfirm.com .
The class in this matter has not yet been certified, meaning you are not currently represented by legal counsel. If you decide not to take any action, you may remain an absent member of the class.
The complaint alleges that the Company issued statements to the market that were inaccurate and misleading. It claims that Soleno minimized safety concerns identified during its Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). In reality, the treatment was associated with higher safety risks than disclosed, along with reduced commercial potential and an increased likelihood of adverse events. As a result, the Company’s public disclosures were materially misleading throughout the class period. Once these issues became known, investors experienced financial losses.
Click here to Join the case to recover your losses.
Investors who acquired the company’s securities between March 26, 2025, and November 4, 2025 (the “Class Period”), are urged to reach out to the firm before May 5, 2026.
You are invited to get in touch with Brian Schall at The Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335 to review your legal rights at no cost. Alternatively, you may connect with the firm through its website at www.schallfirm.com or via email at bschall@schallfirm.com .
The class in this matter has not yet been certified, meaning you are not currently represented by legal counsel. If you decide not to take any action, you may remain an absent member of the class.
The complaint alleges that the Company issued statements to the market that were inaccurate and misleading. It claims that Soleno minimized safety concerns identified during its Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). In reality, the treatment was associated with higher safety risks than disclosed, along with reduced commercial potential and an increased likelihood of adverse events. As a result, the Company’s public disclosures were materially misleading throughout the class period. Once these issues became known, investors experienced financial losses.
Click here to Join the case to recover your losses.
Companies